All News

Article

All RA-ILD deserves a trial of immunomodulation

Richard Conway, MBBChBAO, PhD Nov 10, 2026

The optimum treatment approach in RA-ILD remains an area mired in controversy. This is evident from the contrasting views taken by the 2 recent expert guidelines from ACR and EULAR, which advocate for very different treatment options.

The Usual Suspects: Unmasking Difficult-to-Treat RA #ACR26: IgA-MAA emerged as an independent predictor of D2T-RA, while adipokines showed predictive potential in patients with obesity. The clues may lie beyond clinical factors. @RheumNow https://t.co/g6TGguXggs

https://x.com/Mota_licia_reum/status/2120176208390553910/photo/1

Symptom-Inflammation Phenotypes in Active RA Data from CPIRA cohort (n=283, established active RA), used K-means clustering on PROs + inflammatory markers (SJC28, hsCRP) to find phenotypes. Identified 4 clusters: -C1 (n=117): low-moderate inflammation, low symptoms -C2 (n=77): https://t.co/s8wCEtj3iI

GDF-15: A New Signal for Heart Failure in RA #ACR26 Abstract #2431: In 2,212 RA patients, elevated GDF-15 predicted heart failure independently of traditional CV risk factors, but not atherosclerotic events. @RheumNow #ACR26 https://t.co/ridvwsHLGD

https://x.com/Mota_licia_reum/status/2120175101538607579/photo/1

Can respiratory infections trigger RA-ILD? #ACR26 Abstract 1737: Respiratory infections were associated with subsequent RA-ILD, particularly non-fibrotic disease. RSV showed a particularly strong association (OR 7.06). A potential environmental trigger. @RheumNow #ACR26 https://t.co/3TxiMYgjhO

https://x.com/Mota_licia_reum/status/2120174514927714563/photo/1

Lifestyle modification improved markers of lymphocyte aging & disease activity in 20 adults with RA. Pooled DAS28-CRP improved ~14% over 16 weeks. Immune measures did not differ significantly between exercise/weight-loss coaching and lifestyle counselling. #2803 @Rheumnow #ACR26

Lifestyle interv in older RA pts impacts immune signaling Ab#2803 @RheumNow #ACR26 Exercise, diet, counseling Improved RA activity, peripheral markers of lymphocyte aging with incr naive helper T cells, less senescent/aged cells. Incr immune signaling, assoc w muscle health https://t.co/yCEYst4PoD

Tender-Swollen Joint Difference Thresholds in RA with Fibromyalgia: Data from CPIRA study (n=295) on RA pts either starting or switching DMARDs due to active disease. -TSJD was calculated as the number of tender joints minus swollen joints on standardized 28-joint exams. - 29% https://t.co/WIg1j1O4vz

https://x.com/AdelaCastro222/status/2120168235207446884/photo/1

GLP-1 RAs: A pulmonary game changer in RA? #ACR26 Abstract #1445: Lower pulmonary hypertension (HR 0.47) and mortality (HR 0.69), but no significant ILD benefit. @RheumNow https://t.co/QRKUGNn3Y5

https://x.com/Mota_licia_reum/status/2120167371830915097/photo/1

Can gut #candida trigger #rheumatoid #arthritis? ⬆️candida #albicans gut #microbiome in RA & at-risk RA ⬆️IgA candida in gu Insufficient to cause #IA in mice But silent immune priming ⬆️risk of #arthritis in mice w other hit? Alters TH17 #ACRbest #2832 #ACR26 @ACRheum @RheumNow https://t.co/L3Nva3vzXM

Beyond CD19: engineered islet-specific Tregs in recent-onset T1D GNTI-122, phase 1, single dose 10^8 cells (n=3), 10^9 (n=3), 10^9 + rapamycin (n=10) DRB1*04:01+ only, 78 wk f/u DRB1*04:01 is the RA shared epitope. RA should be next. Jane Buckner @RheumNow #ACR26 https://t.co/KF7FnnPpnz

https://x.com/he67407/status/2120161605300424822/photo/1

Age-related differences in cannabis consumption patterns in pts with RMDs with chronic pain. Cross-sectional, online survey of 865 adults (81% Female, 93% White, 65% with at least a bachelor’s degree) with self-reported RMDs. Chronic pain > 3 months was reported by 82%. RA

A#2826 @RheumNow #ACR26 Transcriptional profile of circulating monocytes assoc w nociplastic pain in RA Key pathways: - NFkB correlates w high pain sensitization - Macrophage activation corr PROMIS pain - Cytokine production LOWER PROMIS fatigue Further study IFN sig w pain sens https://t.co/AVvQLgUPLT

https://x.com/ericdeinmd/status/2120157938845159882/photo/1

Could blood proteins guide JAKi vs TNFi selection? A 7-protein model discriminated opposite 6-month remission outcomes in advanced-therapy-naive RA (AUC 0.75), but performed poorly after prior therapy (0.57). @Rheumnow #2829 #ACR26

Stromal CAR-T: target is the FAPa+ synovial fibroblast Mouse arthritis, CAR-T IV at 1st flare Swelling AUC lower over 3 episodes, all p<0.001 Lining architecture restored Preclinical. FAPa sits outside the joint, off-target depletion decides the path Adam Croft @RheumNow #ACR26 https://t.co/vufSwu4gKU

https://x.com/he67407/status/2120152003259298251/photo/1

#ACR26 @RheumNow Ab#2824 FORWARD - type 2 SLE sx (nociplastic, non-inflamm) Scored Inflammatory sx score (SLAQ), Fibromyalgia survey score -59% had high FM score -Opioid use in combined inflamm/FM group -FM scores did not follow inflamm improv 1 in 6 had peristent nociplastic sx https://t.co/lNwhz4uunA

Not just another ‘JAK’ Ph3 #RCT in active #RA 1 #bDMARD-IR 24w #Gyrocotinib #JAK1/Tyk2 vs Tofacitinib #JAK1 Gyro was superior #ACR50 73% vs 49.5% Replicating Ph2 results Other outcomes gyro>tofa Similar safety ?will results be replicated beyond China #LB21 #ACR26 @RheumNow https://t.co/ggN6X1kfED

#ACR26 @RheumNow Ab#2823 CPIRA (Centralized Pain in RA) - RA observ cohort, change of DMARD at entry, 12 wk 1/4 pts = symptom-dominant phenotype w less inflamm, highest BMI, TJC, FSQ Symptoms do not align with inflamm Distinct profiles remain apparent at 12 wks despite new Rx https://t.co/92EK2P568s

https://x.com/ericdeinmd/status/2120145747899236805/photo/1

Worried about biologics in RA patients who have had cancer? Spanish registry data n=728 11022pt-y bDMARDs across classes were no different (trend better) Always hard to interpret this data type/context but every sign has been reassuring for bDMARDs ABST2409 #ACR26 @RheumNow https://t.co/RYMoYK1WKU

https://x.com/drdavidliew/status/2120119676227469325/photo/1

Way et al. Predicting response to immunomodulators in RA-ILD. Using UIP to predict non response is poor! AUC 0.477. Multivariable model with radiology + clinical features better but still AUC 0.629. Maybe all RA-ILD deserves a trial of immunomodulator? @RheumNow #ACR26 Abstr#2688 https://t.co/KSmzAXXpcP

https://x.com/RichardPAConway/status/2120013580598939783/photo/1

Topics

All News

All RA-ILD deserves a trial of immunomodulation

Do you get our email newsletter?